| Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort. |
26291054
|
Hashibe M, Galeone C, Buys SS, Gren L, Boffetta P, Zhang ZF, La Vecchia C |
Br. J. Cancer |
2015 |
PLCO |
| Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial. |
26291583
|
Shoag J, Halpern J, Eisner B, Lee R, Mittal S, Barbieri CE, Shoag D |
JAMA Oncol |
2015 |
PLCO |
| Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. |
26320383
|
Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM, Ankerst DP, Liss MA |
Eur. Urol. |
2015 |
PLCO |
| Focused Decision Support: a Data Mining Tool to Query the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dataset and Guide Screening Management for the Individual Patient. |
26385814
|
Sharma A, Hostetter J, Morrison J, Wang K, Siegel E |
J Digit Imaging |
2015 |
PLCO |
| Participants' Views of Retention Materials Used in the PLCO Cancer Screening Trial. |
26387707
|
Pretzel SM, Andrews TS, Broski K, Childs JC, Gren LH, Ogden SL, Mabie J, Thomas B, Rozjabek HM, Marcus PM |
Clin Med Res |
2015 |
PLCO |
| Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial. |
26435288
|
Gohagan JK, Broski K, Gren LH, Fouad MN, Higgins D, Lappe K, Ogden S, Shambaugh V, Pinsky PF, O'Brien B, Yurgalevich S, Riley T, Wright P, Prorok PC |
Rev Recent Clin Trials |
2015 |
PLCO |
| PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies. |
26435289
|
Black A, Huang WY, Wright P, Riley T, Mabie J, Mathew S, Ragard L, Hermansen S, Yu K, Pinsky P, Prorok PC, Freedman ND, Hoover RN |
Rev Recent Clin Trials |
2015 |
PLCO |
| Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening. |
26483244
|
Pinsky PF, Kramer BS |
J. Natl. Cancer Inst. |
2015 |
PLCO |
| Fruit and vegetable intakes and risk of colorectal cancer and incident and recurrent adenomas in the PLCO cancer screening trial. |
26559156
|
Kunzmann AT, Coleman HG, Huang WY, Cantwell MM, Kitahara CM, Berndt SI |
Int. J. Cancer |
2015 |
PLCO |
| Multivariate piecewise exponential survival modeling. |
26583951
|
Li Y, Panagiotou OA, Black A, Liao D, Wacholder S |
Biometrics |
2015 |
PLCO |
| Physical activity and benign prostatic hyperplasia-related outcomes and nocturia. |
25010403
|
Wolin KY, Grubb RL, Pakpahan R, Ragard L, Mabie J, Andriole GL, Sutcliffe S |
Med Sci Sports Exerc |
2015 |
PLCO |
| Time to First Morning Cigarette and Risk of Chronic Obstructive Pulmonary Disease: Smokers in the PLCO Cancer Screening Trial. |
25985429
|
Guertin KA, Gu F, Wacholder S, Freedman ND, Panagiotou OA, Reyes-Guzman C, Caporaso NE |
PLoS ONE |
2015 |
PLCO |
| Occurrence of Distal Colorectal Neoplasia Among Whites and Blacks Following Negative Flexible Sigmoidoscopy: An Analysis of PLCO Trial. |
25835747
|
Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Hickey T, Riley T, Church TR, Weissfeld J, Schoen RE, Marcus PM, Prorok PC |
J Gen Intern Med |
2015 |
PLCO |
| Epidemiologic studies of estrogen metabolism and breast cancer. |
25725255
|
Ziegler RG, Fuhrman BJ, Moore SC, Matthews CE |
Steroids |
2015 |
PLCO |
| Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. |
25533883
|
Alford SH, Rattan R, Buekers TE, Munkarah AR |
Cancer |
2015 |
PLCO |
| Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. |
25225425
|
Zhou CK, Pfeiffer RM, Cleary SD, Hoffman HJ, Levine PH, Chu LW, Hsing AW, Cook MB |
J. Clin. Oncol. |
2015 |
PLCO |
| Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. |
25066872
|
Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK |
J. Urol. |
2015 |
PLCO |
| Lung cancer screening: identifying the high risk cohort. |
25984362
|
Marcus MW, Raji OY, Field JK |
J Thorac Dis |
2015 |
PLCO |
| GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes. |
26429724
|
Lee M, Williams KA, Hu Y, Andreas J, Patel SJ, Zhang S, Crawford NP |
Clin. Exp. Metastasis |
2015 |
PLCO |
| Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial. |
25982801
|
Liss MA, Xu J, Chen H, Kader AK |
Prostate |
2015 |
PLCO |
